key: cord-0908323-hed6x22m authors: Smits, Veronique A.J.; Hernández-Carralero, Esperanza; Paz-Cabrera, María Cristina; Cabrera, Elisa; Hernández-Reyes, Yeray; Hernández-Fernaud, Juan Ramón; Gillespie, David A.; Salido, Eduardo; Hernández-Porto, Miriam; Freire, Raimundo title: The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients date: 2021-03-05 journal: Biochem Biophys Res Commun DOI: 10.1016/j.bbrc.2021.01.073 sha: 04e0c2d7d174f71f17bc1af83739951a55ce2a3a doc_id: 908323 cord_uid: hed6x22m In order to control the COVID-19 pandemic caused by SARS-CoV-2 infection, serious progress has been made to identify infected patients and to detect patients with a positive immune response against the virus. Currently, attempts to generate a vaccine against the coronavirus are ongoing. To understand SARS-CoV-2 immunoreactivity, we compared the IgG antibody response against SARS-CoV-2 in infected versus control patients by dot blot using recombinant viral particle proteins: N (Nucleocapsid), M (Membrane) and S (Spike). In addition, we used different protein fragments of the N and S protein to map immune epitopes. Most of the COVID-19 patients presented a specific immune response against the full length and fragments of the N protein and, to lesser extent, against a fragment containing amino acids 300–685 of the S protein. In contrast, immunoreactivity against other S protein fragments or the M protein was low. This response is specific for COVID-19 patients as very few of the control patients displayed immunoreactivity, likely reflecting an immune response against other coronaviruses. Altogether, our results may help develop method(s) for measuring COVID-19 antibody response, selectivity of methods detecting such SARS-CoV-2 antibodies and vaccine development. J o u r n a l P r e -p r o o f Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) infection causes the coronavirus disease 2019 (COVID-19) [1] . COVID-19 has spread quickly over the world and is responsible for more than a million deaths despite severe containment measures in many countries (https://covid19.who.int). To limit the spread of the disease, efforts are undertaken by the scientific community to detect patients that are undergoing or have passed the infection [2] . Also, many research centers and pharmaceutical companies are working on the development for an effective vaccine that protects against COVID-19 [3, 4] . Upon infection, the immune system recognizes and tries to neutralize the SARS-CoV-2 virus particle. Here we investigated which protein(s) and/or protein fragments from the SARS-CoV-2 virus particle induce a humoral immune response in patients. We believe our work contributes to an accurate method to detect patients that suffer COVID-19 but also gives information on what are the most immunoreactive parts of the virus, information that might contribute to developing an effective vaccine. J o u r n a l P r e -p r o o f Full length N and M proteins from SARS-CoV-2 and fragments containing amino acids 1- were transfected with GFP-tagged SARS-CoV-2 N protein and extracts were generated by urea-SDS buffer as described before [6] . The recombinant His-tagged full length SARS-CoV-2 N protein was used to immunize a rabbit. Serum was obtained after five immunizations and used in experiments of Figure S1 . The anti-GFP antibody was described before [7] . The quantification analysis was performed based on the dot blot results using the ImageQuant TL 1D v8.1 software following analysis performed by integrating the levels of pixels (volume) surrounded by a circular selection. Density of immunoreactive dots is reported as arbitrary units (a.u.). The data are expressed as mean (bar) with the 25th -75th percentile range (box) and the 10th -90th percentile range (whiskers). A two-way analysis of variance (ANOVA) followed by Sidak's multiple comparisons test was applied for statistical significance determination (****P < 0.0001, **P < 0.01, *P < 0.05). The viral particle of SARS-CoV-2 contains the viral positive-sense, single-stranded RNA genome that is surrounded by a lipid bilayer that contains the spike (S), nucleocapsid (N), membrane (M) and envelope (E) proteins [8] . The S protein is a large protein (1273 amino acids) that is processed into two subunits, S1 (amino acids 14 to 685) and S2 (amino acids 686 to 1273). S1 is responsible of the binding to the ACE2 receptor in the host cell and S2 subunit facilitates membrane fusion. Different subdomains are described in the S1 and S2 subunits, including a Receptor Binding Domain (RBD) comprising amino acids 319-541, that binds to the human ACE2 receptor with high affinity [9] (Fig. 1A) . The N protein is the most abundant viral protein and binds to the viral RNA forming the core of a ribonucleoprotein complex [10] . The Nucleocapsid protein contains an N-terminal Domain (NTD) that functions in the genomic RNA binding, which is connected by a central serinerich linker region (LKR) to the and C-terminal Domain (CTD), involved in dimerization and also with RNA-binding activity [8, 11] (Fig. 1A) . The E protein is a membrane protein of only 75 amino acids and contains a hydrophobic region. Together with the M protein of 221 amino acids, containing 3 transmembrane domains, the E protein plays a role in viral assembly [12] (Fig. 1A) . In order to study the patient immune response to the SARS-CoV-2 viral particle, we set out to investigate the antibody response to the different virus proteins in COVID-19 patients´ sera. For this, different SARS-CoV-2 proteins/protein fragments were cloned into a plasmid to produce his-tagged proteins, that were subsequently expressed in E. Coli, purified and quantified (Fig. 1A) . Due to technical difficulties, we could not purify the E protein or a fragment containing the C-terminal part of the S2 subunits, but we successfully purified 4 J o u r n a l P r e -p r o o f different overlapping regions of the S protein, 3 regions of the N protein together with the full length M and N proteins ( Fig. 1A and 1B) . An immunoglobulin G (IgG) antibody response against the full length S protein was observed in COVID-19 patients, from 15 days after appearance of the first symptoms [13] . To study the possible differential response to the different structural proteins of the virus, we set up a simple assay to detect specific IgGs. First preliminary experiments were performed with an anti-N protein antibody that we raised in rabbit using the full length N protein as immunogen. As shown in Supplementary Fig. S1A , the antibody very specifically (at dilutions up to 1:8,000) recognized the overexpressed N-protein fused to GFP by western blot, but also worked in a dot blot assay recognizing small amounts of purified recombinant N protein spotted on a nitrocellulose membrane ( Supplementary Fig. S1B ). After preliminary tests to determine the optimal amounts of recombinant proteins spotted, dot blot assays with the 4 fragments of the S protein, 3 of the N protein, together with the full length M and N proteins were performed (see schedule in Fig. 1C, top) . These dot blots were probed with the sera of patients from our hospital that were diagnosed as COVID-19 positive by RT-PCR tests. We also included sera of control patients collected before the pandemic, in February 2019. Fig. 1C (bottom) shows a representative example from a COVID-19 patient and control patient against all structural proteins/fragments used in this study. Supplementary Fig. S2 and S3 show all the dot blots obtained for all COVID-19 and control patients, respectively. The results demonstrate an IgG antibody response in almost all COVID-19 patients, whereas the general response in control patients was low, as expected. Next, all dot blots were quantified, and the data were analyzed. As shown in Fig. 2A The new SARS-CoV-2 coronavirus has quickly spread over the world. Due to its potent capacity for infection and the fact it can cause severe morbidity and mortality, the virus became a serious health threat that led to economic and social disruptions. Here we compared the humoral immune response against different fragments or full length proteins of SARS-CoV-2 in serum from verified COVID-19 patients to that of control patients. Our observations demonstrate that dot blot analysis is a relatively simple and efficient technique to examine the humoral immune response to SARS-CoV-2. Analyzing the response to the different proteins of SARS-CoV-2 showed that the N protein is the most immunogenic among all analyzed proteins. While a strong IgG antibody response to the N protein was also observed by others [11] , the immunogenic regions were not mapped nor was its relative immunogenicity compared to other viral proteins. Here we show that multiple regions of the N protein elicit an immune response in patient serum that is relatively more potent than that elicited by other viral proteins. Interestingly, also the N protein of the related SARS-CoV was shown to be highly immunogenic [14] . In contrast, even though the overall IgG response to the SARS-CoV-2 S protein was lower, possibly due to the glycosylation status of this protein [15] , the majority of the COVID-19 patients did trigger a response to a region in the S1 subunit of the protein, containing the RBD. Despite the clear overall IgG response to the N-protein in the majority of the patients, not all patients showed this reaction. One explanation could be that the adaptive immune response of these patients was still early and IgG titers were still very low. Alternatively, J o u r n a l P r e -p r o o f innate immunity could have played a role in defense against the SARS-CoV-2 infection in these patients [16, 17] . In addition, a few control patients displayed an IgG response to the SARS-CoV-2 N proteins, suggesting that there might be some reactivity with other coronaviruses. Antibody testing is not only important to identify those who have gained immunity but also in understanding the prevalence of the virus in the community. In addition, we believe that A Novel Coronavirus from Patients with Pneumonia in China Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape The COVID-19 vaccine development landscape Evolution of the COVID-19 vaccine development landscape A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Rad9B responds to nucleolar stress through ATR and JNK signalling, and delays the G1-S transition The Ddc2/ATRIP checkpoint protein monitors meiotic recombination intermediates Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein Biochemical characterization of SARS-CoV-2 nucleocapsid protein Coronavirus envelope protein: current knowledge Virological assessment of hospitalized patients with COVID-2019 Serological assays for emerging coronaviruses: challenges and pitfalls Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses